8/6/2019 GCP Presentation 6-1-10
1/66
General Principles for
Meeting RegulatoryResponsibilities
Terry VandenBosch, RN, PhD, CIP, CCRPSenior Research Compliance AssociateOffice of Human Research Compliance ReviewUniversity of MichiganJune 1, 2010
8/6/2019 GCP Presentation 6-1-10
2/66
Todays Discussion
Describe Best Research Practices (BRP) andGood Clinical Practices (GCP)Compare GCP requirements for FDA regulatedstudies and regulatory requirements for non-FDAregulated studiesIdentify common sense principles for
implementing best practices and GCP in clinicalstudies
8/6/2019 GCP Presentation 6-1-10
3/66
What is Best Practice
Experience-basedEvidence-based?Effective and efficient practices to meet
1) ethical principles2) federal regulations & guidance4) state laws & practice acts5) university policies and procedures6) any applicable study SOPs
Best Practices = Responsible Research Practices
8/6/2019 GCP Presentation 6-1-10
4/66
Ultimate Goal:
Responsible Research Practices
The University of Michigan is committed to the
highest standards of ethical behavior by faculty,staff, and students engaged in the conduct andadministration of research and other scholarlyactivity.
UM Provost Policy Statement on Academic and Research Integrity
8/6/2019 GCP Presentation 6-1-10
5/66
Ethical Principles & BestPractices
Ethical principles inform decision-making and basisfor federal regulations and guidancePast abuses stimulate use of Best Practices
NuremburgTuskegee syphilis studyWillowbrook retarded children hepatitis study
Are these ethical lapses and abuses all in the past?Nicole Wan (healthy volunteer- died), 1996
Jesse Gelsinger (ineligible-died), 1999Ellen Roche (healthy volunteer-died), 2001Inadequate monitoring with overdose of pediatric subjects-Pfizer FDA warning letter, April 9, 2010
8/6/2019 GCP Presentation 6-1-10
6/66
Ethical Principles-Belmont
Belmont Report 1979 Summarized ethical principals identified by National
Commission for the Protection of Human Subjects Prompted by the Tuskegee Syphilis Experiment and
the Willowbrook hepatitis study 3 basic ethical principles: (1) Respect for persons (2) Beneficence (3) Justice
Peter Buxtun, PHSvenereal diseaseinvestigator, theTuskegee whistle -blower
The Tuskegee Study Groupwere invited to receive"special treatment", whichwas actually a diagnosticlumbar puncture
http://en.wikipedia.org/wiki/Image:Buxton_media.jpg8/6/2019 GCP Presentation 6-1-10
7/66
Respect for Persons
Ethical convictionsAcknowledge autonomy of the individualProtect those with diminished autonomy
Applying the principleInformed consent
The elements of informed consentInformation, comprehension, voluntaryVulnerable populations
8/6/2019 GCP Presentation 6-1-10
8/66
BeneficenceEthical convictions
Do no harmMaximize possible benefits
Minimize possible harms
Applying the principleInvestigator & IRB
Minimize risksWeigh risks and benefitsWhen appropriate, a plan to monitor andensure safety
8/6/2019 GCP Presentation 6-1-10
9/66
JusticeEthical Convictions
Fairness in distribution of burdens and benefits ofresearch participation
Applying the principleInvestigator-subject selectionIRB asks Is the selection of subjects equitable?
8/6/2019 GCP Presentation 6-1-10
10/66
RegulationsRegulations developed in response to egregious, harmfulresearch conductDeveloped on ethical principlesCongressional legislation signed into law by PresidentLaws interpreted in CFR (Code of Federal Regulations)by responsible federal agency
CFR regulations detail how law is implementedNoncompliance with CFR may result in criminalprosecution, fines, sanctions or debarment from research
8/6/2019 GCP Presentation 6-1-10
11/66
8/6/2019 GCP Presentation 6-1-10
12/66
Federal Guidance andInformation Sheets
Published by federal agencies to provide moreinformation or to recommend best practicesInterprets application of regulationsCurrent thinkingNOT legally bindingFDA An alternative approach may be usedif such approach satisfies the requirements ofthe applicable statue, regulations, or bothGuidance should be met
8/6/2019 GCP Presentation 6-1-10
13/66
University of MichiganPolicies and Procedures
Standard Practice GuideApproved by RegentsSection 303, http://spg.umich.edu/section/303
Human Research Protection Program(HRPP) Operations Manual
http://www.hrpp.umich.edu/om/
IRB Guidance & SOPsSee IRB websites
8/6/2019 GCP Presentation 6-1-10
14/66
What is GCPA type of Best Practice term coined by theInternational Conference on Harmonization(ICH) and used by FDARefers to FDA regulations, guidance and notices
for Drugs, Devices & BiologicsFDA assures the safety and efficacy of pharmaceuticals, biologics, and medical devices onthe market in the U.S.A.
What entities covered by FDA GCP?IRBInvestigatorResearch Sponsor
NIH- Scientific and ethical standards of human
subject research
8/6/2019 GCP Presentation 6-1-10
15/66
ICH E6 InternationalConference on Harmonization
Multi-national body, USA, EU & Japan, est. 1989Meets periodically to resolve different technicalrequirements for drug registration
Goal: Create guidelines and standards for conductingclinical trials allowing sponsors to generate a single setof data to meet submission requirements of the threeregions
Originally based on ethical principles from theDeclaration of Helsinki-1964 with revisionsAdopted as guidance for drugs/biologics by FDAin 1997Also used by FDA in reference to devices
8/6/2019 GCP Presentation 6-1-10
16/66
ICH-E6 GCP DefinitionA standard for the design, conduct,performance, monitoring, auditing, recording,analyses , and reporting of clinical trials that
provides assurance that:the Data and Reported Results are Credible ,and Accurate , and thatthe Rights , Integrity , and Confidentiality of TrialSubjects are ProtectedAdopted as guidance by FDA in 1997
= Quality Data
= Ethics
8/6/2019 GCP Presentation 6-1-10
17/66
FDA Regulations and ICHGuidelines
Companies that wish to have study data acceptedby the regulatory agencies in the US, EU, and/orJapan need to follow the ICH guideline.Differences between FDA Regulations and ICHGCP Guidelines:
ICH Guideline states general principles is moreprescriptive than regulationse.g., 21 CFR 50 requires signature and date of subjectwhile ICH E6 says one should also have the signature ofthe investigator.
8/6/2019 GCP Presentation 6-1-10
18/66
Why GCP?Failures
Ethical AtrocitiesPreventable Research Deaths/InjuryScientific Fraud
Subject safetyPublic trust and support of research missionAssure valid data for evidence-based Health CareDrug development trajectory long, arduous,expensive (GCP assures safety and quality data)Useful products brought to market with known safetyprofile and effectivenessThe better the GCP-the sooner the product isavailable for patients
8/6/2019 GCP Presentation 6-1-10
19/66
Best Practices, GCP & Typesof Studies
Investigator InitiatedMay or may not be FDA regulated
NIH (HHS) supported
45 CFR 4617 Federal agencies and the common rulePart A of 45 CFR 46e.g., Dept. of Energy, Dept. of Education
FDA Regulated21 CFR 312 Drugs & Biologics21 CFR 812 Devices21 CFR 50 Protection of Human Subjects21 CFR 56 Institutional Review Boards
8/6/2019 GCP Presentation 6-1-10
20/66
Research Clinical Trials BestPractices and ICH E6 GCP
Both can be viewed as a series of key activitiesor practices
Order of activities may vary and may be simultaneousMultiple parties participate but PI remains accountable
Study scientific and ethical quality achieved bydefining key study best practices and assuringoversight to implement them
8/6/2019 GCP Presentation 6-1-10
21/66
Best Practices Key ActivitiesObtain Informed consentProvide for Subject Safety & Medical CareFollow the IRB approved protocol or submit amendment to IRBMaintain Confidentiality
Record keeping-Maintain accurate, current, organized records andsubmit reportsMaintain communication with IRBProvide appropriate oversight of qualified staffFDA-Investigational Product AccountabilityFDA-Essential Documents BinderAdditional areas
Conflict of interestCommunication with sponsor (FDA)Shipping regulations
8/6/2019 GCP Presentation 6-1-10
22/66
People and Paper Skills
NegotiationCommunicationTime managementRecord keepingComputerOrganization
Oversight of other research staffDetail-orientedKnowledge of regulations and their applicationIntimate knowledge of protocol
8/6/2019 GCP Presentation 6-1-10
23/66
8/6/2019 GCP Presentation 6-1-10
24/66
Informed Consent as aProcess
Interpersonal communication skills assess subject understandingand motivation to participateInformed consent is freely given and is obtained from each subjectprior to study participation
The consent discussion is in language understandable to theparticipant or the representative and is done by a qualified personThe consent process provides sufficient opportunity for theparticipant or the participants legally authorized representative toconsider whether to participate
The consent process minimizes the possibility of coercion or undueinfluence (Research is not the same as therapeutic txmt)The consent discussion is free of exculpatory languageThe IRB approved document without any changes and with theelements of informed consent is used
Childrens assent & Parental Permission Adapted from AAHRPP, 2009
8/6/2019 GCP Presentation 6-1-10
25/66
Informed Consent MonitoringPrivacy respectedVoluntaryConducted as a process by PIProcess follows the IRB approved protocol
Waiver of consent possibleCopy of consent given to subjectConsent signed prior to any study proceduresRe-consent completed and documented asappropriate100% of consents used correct IRB approvedversion and were appropriately signed anddated
8/6/2019 GCP Presentation 6-1-10
26/66
What does the public think?
29%
9% 10%
40%
13%
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
A person whogives blood
A person whovolunteers totake part in aclinical trail
A person whoraises money for
charity byrunning in a race
A person whodonates an
organ
Not sure/Refused
P e r c e n t
N=900
Which one of the following do you think makes a greatercontribution to mankind?
CISCRP/ODC Survey, 12/2006
8/6/2019 GCP Presentation 6-1-10
27/66
It is a confusing time to be asubject-or to be thinking about
becoming one
Moreno, 2001
8/6/2019 GCP Presentation 6-1-10
28/66
Subject Safety
Provide for Subject Safetyand Clinical Care
8/6/2019 GCP Presentation 6-1-10
29/66
Adverse Events & Harms.
Adverse event (AE) definedPrevent, monitor for, identify, provide immediate care for,track, analyze cause, report to IRB, may submit protocolamendment or changes to consent document & notifySponsor (FDA)IRBMED Guidance and timetable for reporting AEs athttp://med.umich.edu/irbmed/ae_orio/ae_report.htmHarms
Physical
PsychosocialSocialEconomicLegalDignitary
8/6/2019 GCP Presentation 6-1-10
30/66
What Can Result in Harms?
The protocol/treatmentSide effects of drugs/biologics or adverse device effectsNOT following the protocolNOT maintaining up-to-date recordsNOT maintaining communication with investigator and/or
study sponsorPrevent harmQualified person monitors overall studyMonitor laboratory results and tests and treat as appropriateMay withdraw subject from study
Know emergency procedures for breaking a study blindKeep primary care provider in communication as appropriateAEs are graded by
SeriousnessRelatedness to the study
Expected/Unexpected
8/6/2019 GCP Presentation 6-1-10
31/66
The Protocol
Follow the Protocol or Amend it
8/6/2019 GCP Presentation 6-1-10
32/66
The Tension in Research
The principal duty of a physician is to thewell-being of the individual.The principal duty of society (social ethics) isto the greatest good for the greatest numberof people.Research is protocol drivenClinicians often want to adapt the protocol foran individual
8/6/2019 GCP Presentation 6-1-10
33/66
Know and Follow the ProtocolChanges to the protocol, may not be initiated without IRB reviewand approval except when necessary to eliminate apparentimmediate hazards to the subject.Read it
FDA-each person on study team signs it
Protocol Readily AvailableNo mix ups-Clearly label current version
Follow itPrevent and track any protocol deviations
Notes to file-circumstances, CAPAReport to IRB and sponsor as applicableAmend protocol with IRB as needed
Follow randomization proceduresIf applicable, procedures follow data safety and monitoring plan(DSMP) submitted to IRB and funding agencies
8/6/2019 GCP Presentation 6-1-10
34/66
Confidentiality
Maintain Confidentiality
8/6/2019 GCP Presentation 6-1-10
35/66
Data Confidentiality & Security:Outcomes
Data maintained according to IRB approvedprotocolAccess to confidential data is restricted
Safe & secure storageDont share passwords!Mobile device security for researchers athttp://www.safecomputing.umich.edu/MDSUM Electronic data security Questions to GuideResearch Protections at OHRCR websitehttp://www.ohrcr.umich.edu/news/electronicdata.pdf
8/6/2019 GCP Presentation 6-1-10
36/66
Implications for Confidentiality
Being notified only, with no re-consent or opt out process, before their information goes to a national database
47% completely unacceptable20% somewhat unacceptableNo notification or re-consent at all, before their information is sent to a national database
54% completely unacceptable16% somewhat unacceptable
How much do current and potential subjectswant to be informed, give consent and maintain
confidentiality of their data?
8/6/2019 GCP Presentation 6-1-10
37/66
Record Keeping &Reports
Maintain Accurate, Current,Organized Records and SubmitReports
8/6/2019 GCP Presentation 6-1-10
38/66
Study FilesOrganized, accurate, up-to-dateDirect/Indirect subject identifiers
Direct-subject identifiers stored with dataIndirect-subject identifiers in key & not stored with data
Informed consent-stored with files?FDA-Complete, sign and submit FDA Form 1572Work efficiently
Study schema of subject progress for complex procedures
Checklist of forms completedMaintain records for:
FDA- two years after FDA approves NDANIH- three years after study terminatedHIPAA- six years after study terminated
8/6/2019 GCP Presentation 6-1-10
39/66
ALCOA (FDA)
FDA Documentation GuidanceA Attributable (who, when)
L Legible (readable, pen, no white out, single line)C Contemporaneous (up-to-date)O Original (source document)
A Accurate (verifiable with source)
8/6/2019 GCP Presentation 6-1-10
40/66
Source Data and Documents(FDA)
All clinical trial information should be recorded, handled,and stored in a way that allows its accurate reporting,interpretation, and verification
Source Document DefinitionOriginal documents, data, and records, (e.g., ALL study records suchas visits, CRF/Data Collection Forms, and,Subjective self-report instruments, hospital, clinical and office charts,laboratory notes, notes to file, subject diaries, checklists, pharmacy
dispensing records, recorded data from automated instruments, X-Rays, digital records
Source DataGenerate and Keep source documents in original recordsMay be using Electronic Data Capture (EDC)
8/6/2019 GCP Presentation 6-1-10
41/66
The IRB
Maintain Communicationwith the IRB
8/6/2019 GCP Presentation 6-1-10
42/66
IRB Communications andSubmissions
Interact with IRBAsk questionsGet to know UM IRB contacts
Initial IRB submission and approvalOngoing oversight
AEs, protocol deviations, unanticipated problems, DSMCreports or safety officer reports, UM OHRCR report, new
information that changes risk/benefit of studyparticipationContinuing review
Terminate a studyDont let it expire!
8/6/2019 GCP Presentation 6-1-10
43/66
Study Oversight &Qualifications
8/6/2019 GCP Presentation 6-1-10
44/66
Overall PI/InvestigatorResponsibilities
Ensure a study is conducted according to theprotocol or study plan and applicable
regulationsFDA Form 1572Protect the rights, safety, and welfare ofsubjects under the investigators careFDA-Control drugs, biological products, anddevices under investigation
FDA Guidance for Industry: Investigator Responsibilities, Oct 2009
8/6/2019 GCP Presentation 6-1-10
45/66
Study Oversight by thePI/Investigator
Are individuals who are delegated studytasks qualified to perform them?Have individuals received training to theprotocol and to the tasks?Oversight and involvement in ongoingconduct of the studyWhere reasonably possible, oversight of 3 rdparties
Guidance for Industry: Investigator Responsibilities, Oct. 2009
8/6/2019 GCP Presentation 6-1-10
46/66
Adequate Resources
Appropriate facilitiesAppropriate equipment
Correct equipment available
CalibratedPreventive maintenanceStudy staff training
Proper laboratory facilities (FDA=CLIA certified)
Reference ranges for laboratory testsDetails of analytical methodsQuality assurance information
8/6/2019 GCP Presentation 6-1-10
47/66
8/6/2019 GCP Presentation 6-1-10
48/66
Study logs & Oversight
Delegation log with study roles, tasks anddates worked on studySignature log with initials logTrain to protocolTraining logStay up-to-date on subject and overall studyprogress
Regular staff meetings (FDA-take minutes)
8/6/2019 GCP Presentation 6-1-10
49/66
InvestigationalProduct (FDA)
Accountability for theInvestigational Product
8/6/2019 GCP Presentation 6-1-10
50/66
Investigational Product
Process investigational productReceipt (shipping) and DispensingLabelingAccountability to reconcile records for each tablet,
compounded drugSecure storage of device & device returnReturn/Destroy drug as determined by sponsorInterface with Investigational Drug Services /
Biomedical Engineering staff, as neededInvestigational products should bemanufactured, handled, and stored inaccordance with applicable goodmanufacturing practice (GMP)
8/6/2019 GCP Presentation 6-1-10
51/66
Essential Documents(FDA)
Maintain Study Binder
8/6/2019 GCP Presentation 6-1-10
52/66
Binder Index
1. Contents2. Subject Logs and Lists3. Contact Logs and Monitoring
4. Communications: General5. Protocol and Amendments6. Case Report Forms7. Investigator Information8. IRBMED Documents9. Laboratory Information
8/6/2019 GCP Presentation 6-1-10
53/66
Binder Index (contd)
10. Equipment11. Investigational Product Information12. Investigational Product Accountability
Records13. Adverse Events/Effects14. Investigator Meeting Documents15. Regulatory Information
16. Study Reports17. References18. Contracts and Grants19. Patient Data
8/6/2019 GCP Presentation 6-1-10
54/66
Additional Best Practices
Conflict of Interest DisclosureApplies to all members of the study teamIncludes spouses and dependentsMay have a management planFDA forms for financial disclosure from sponsor
Communication with sponsor (FDA)Annual reports to sponsorMaintain ALL sponsor communications
Letters, reports, emails, phone log, faxesReport AEs and unanticipated problemsReport protocol deviationsMonitoring log/visits
8/6/2019 GCP Presentation 6-1-10
55/66
Shipping Regulations for Biologics
University personnel who ship infectious substances includingpatient (clinical) specimens, human-derived researchmaterials, infectious micro-organisms, certain genetically-modified organisms, etc. must complete a training program
prior to shipping infectious or biological substances.The Department of Occupational Safety and EnvironmentalHealth (OSEH) offers the IATA/DOT Shipping InfectiousSubstances Class on a monthly basis. More information and
schedule can be found on the OSEH websitewww.oseh.umich.edu.
Those who complete training receive a trainingcertificate which is valid for two years.
8/6/2019 GCP Presentation 6-1-10
56/66
Overall
Legal or regulatory is not always adequateA personal commitment to integrity needs to becoupled with a firm understanding of BestPracticesThe public support of research rests on its trustof scientists, scholars and the institutions
Individual actions can bolster trust andconfidence or, unfortunately, undermine it aswell
8/6/2019 GCP Presentation 6-1-10
57/66
FDA GCP BIMO Program
Clinical Investigator InspectionSponsor/Monitor/CRO InspectionInspection programs allow the agency to
determine:Adherence to applicable regulationsValidity of studies in support of pending marketingapplicationsWhether the rights and safety of subjects havebeen protected
FDA Common Investigator
8/6/2019 GCP Presentation 6-1-10
58/66
FDA Common InvestigatorDeficiencies
Failure to follow the investigational plan &Protocol deviations (38%)Inadequate recordkeeping, sourcedocumentation, case hx, record retention (27%)Inadequate accountability for investigationalproduct, shipping, handling, storage, labeling
(10%)Inadequate subject protection-including informedconsent (11%) and adverse event (8%) issues
Toth-Allen, J. APEC GCP Inspection Workshop, 2008
8/6/2019 GCP Presentation 6-1-10
59/66
Most Common FDA SponsorDeficiencies
Inadequate monitoringFailure to bring investigators into
complianceInadequate accountability for theinvestigational product
8/6/2019 GCP Presentation 6-1-10
60/66
Selected Recent OHRPNoncompliance Determinations
Informed ConsentFailure to obtain the legally effective informed consent of subjects orof the IRB to appropriately waive the requirements to obtaininformed consent
Failure to document informed consent or of the IRB to appropriatelywaive the requirements to document informed consentFailure to provide a copy of the informed consent document (ICD) tothe subject or the subject's legally authorized representativeInadequate ICD for specific research/lack of basic elements
Inadequate ICD for specific research/lack of additional elementsICD language too complexExculpatory language in ICDsEnrollment procedures did not minimize possibility of coercion orundue influence
8/6/2019 GCP Presentation 6-1-10
61/66
Selected Recent OHRPNoncompliance Determinations
Initial and continuing reviewResearch conducted without IRB review and/or approvalIRB lacks sufficient information to make determinations required forapproval of researchInadequate IRB review at convened meetings
IRB review of protocol changesChanges to research initiated without IRB review and approvalInadequate IRB review and/or approval of protocol changes
IRB membership, expertise, staff support and workloadIRB documentation, findings and procedures
OHRP, http://www.dhhs.gov/ohrp/compliance/findings.html#D20
8/6/2019 GCP Presentation 6-1-10
62/66
Questions?
8/6/2019 GCP Presentation 6-1-10
63/66
ResourcesUM IRBMED & HBHS WorkshopsJoin MICHR research coordinator email networkClinical Trials Network (Duke U)
Forms, education, etc. at https://www.ctnbestpractices.orgFDA Device Advice & training
http://www.fda.gov/medicaldevices/deviceregulationandguidance/default.htmVirtual Regulatory Binder
http://www.partners.org/phsqi/vrb/files/index.htmNIH-Office of Human Subject Research
http://ohsr.od.nih.gov/
OHRP Guidance documentshttp://www.dhhs.gov/ohrp/policy/
ICH E6http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf
http://www.dhhs.gov/ohrp/policy/http://www.dhhs.gov/ohrp/policy/8/6/2019 GCP Presentation 6-1-10
64/66
ICH E6 PrinciplesClinical Trials should be conducted in accordance with theethical principles that have their origin in the Declaration ofHelsinki and that are consistent with applicable regulatoryrequirements.
Foreseeable risks should be weighed against anticipatedbenefits for the individual and for society as a whole; a trialshould only be initiated if anticipated benefits justify the risks.The rights, safety and well being of the trial subjects are themost important considerations and should prevail overinterests of science and society.The non-clinical and clinical information on an investigationalproduct should be adequate to support the proposed clinicaltrial.
8/6/2019 GCP Presentation 6-1-10
65/66
ICH E6 Principles
Clinical trials should be scientifically sound, and describedin a clear, detailed protocol.A trial should be conducted in compliance with the protocoland amendments that have received prior IRB approval.
The medical care given to, and medical decisions made forsubjects should always be the responsibility of a qualifiedphysician.Each individual involved in conducting a trial should bequalified by education, training, and experience to performhis or her respective task(s).Freely given informed consent should be obtained fromevery subject prior to clinical trial participation.
8/6/2019 GCP Presentation 6-1-10
66/66
ICH E6 PrinciplesAll clinical trial information should be recorded, handled,and stored in a way that allows its accurate reporting,interpretation, and verification.The confidentiality of records that could identify subjects
should be protected, respecting the privacy andconfidentiality rules in accordance with the applicableregulatory requirements.Investigational products should be manufactured, handled,and stored in accordance with applicable goodmanufacturing practice (GMP). They should be used inaccordance with the approved protocolSystems with procedures that assure the quality of everyaspect of the trial should be implemented.